Related Experiment Videos
Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists
M Madan1, J C Blankenship, S D Berkowitz
1Duke Clinical Research Institute, Durham, North Carolina 27715, USA.
Insights
Platelet glycoprotein IIb/IIIa receptor antagonists can cause bleeding complications. Strategies like adjusted heparin and early sheath removal may reduce bleeding risks in patients undergoing procedures.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Platelet glycoprotein (GP) IIb/IIIa receptor antagonists are increasingly used in percutaneous coronary interventions (PCI) and acute ischemic syndromes.
- Bleeding complications are a significant limitation to the effectiveness of GPIIb/IIIa blockade.
Purpose of the Study:
- To identify predictors of bleeding events in patients receiving GPIIb/IIIa inhibitors.
- To propose strategies for reducing bleeding complications associated with GPIIb/IIIa inhibitor use, particularly in the context of PCI.
Main Methods:
- Review of baseline characteristics associated with bleeding in patients on GPIIb/IIIa antagonists.
- Analysis of procedural factors influencing bleeding risk in PCI patients receiving GPIIb/IIIa inhibitors.
- Proposal of evidence-based strategies to mitigate bleeding complications.
Main Results:
- Predictive factors for bleeding include older age, low body weight, evolving myocardial infarction, and female sex.
- In PCI, bleeding risk, especially at the femoral access site, may be reduced by using low-dose, weight-adjusted heparin (70 U/kg), avoiding postprocedural heparin, and early vascular sheath removal.
Conclusions:
- Bleeding is a key concern with GPIIb/IIIa inhibitors.
- Specific patient characteristics and procedural adjustments can help minimize bleeding risks, improving patient safety and treatment outcomes.
Abstract:
Platelet glycoprotein (GP) IIb/IIIa receptor antagonists are being used with increasing frequency in the settings of percutaneous coronary interventions and acute ischemic syndromes. The development of bleeding complications following GPIIb/IIIa blockade represents a significant limitation to its effectiveness. Baseline characteristics predictive of future bleeding events in patients receiving platelet GPIIb/IIIa receptor antagonist include older age, low body weight, evolving myocardial infarction, and female sex. In patients undergoing percutaneous coronary interventions with adjunctive GPIIb/IIIa inhibition, the risk of bleeding, particularly from the femoral vascular access site, may be reduced through the use of low-dose, weight-adjusted heparin (70 U/kg), avoidance of postprocedural heparin, and early vascular sheath removal. Strategies to reduce the incidence of bleeding complications in patients receiving GPIIb/IIIa inhibitors are proposed in this article.